Replies to post #240890 on Biotech Values

[DewDiligence]

(ENTA)—Shionogi antiviral is teratogenic—>out_of_contention_for_best-in-class_COVID_drug:

https://www.bloomberg.com/news/articles/2022-04-13/shionogi-falls-most-in-decade-on-birth-defect-risk-of-covid-pill

One fewer serious competitor for ENTA's EDP-235.

Shionogi’s stock (4507.T) closed -11% in Tokyo today.